FDA widens US safety inquiry into AstraZeneca coronavirus vaccine
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 22, 2022
SUNDAY, MAY 22, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
FDA widens US safety inquiry into AstraZeneca coronavirus vaccine

Coronavirus chronicle

Reuters
01 October, 2020, 11:15 am
Last modified: 01 October, 2020, 11:19 am

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • China relaxes some Covid test rules for US, other travellers
  • US reopens embassy in Kyiv after closure forced by war
  • Monkeypox cases are on rise in Europe and US, here is why
  • US to suggest tariffs on Russian oil as alternative to embargoes

FDA widens US safety inquiry into AstraZeneca coronavirus vaccine

Regulators in the UK, Brazil, India and South Africa have allowed AstraZeneca to resume its clinical trials there

Reuters
01 October, 2020, 11:15 am
Last modified: 01 October, 2020, 11:19 am
A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020. Photo:Reuters
A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020. Photo:Reuters

The US Food and Drug Administration has broadened its investigation of a serious illness in AstraZeneca Plc's Covid-19 vaccine study and will look at data from earlier trials of similar vaccines developed by the same scientists, three sources familiar with the details told Reuters.

AstraZeneca's large, late-stage US trial has remained on hold since Sept. 6, after a study participant in Britain fell ill with what was believed to be a rare spinal inflammatory disorder called transverse myelitis.

The widened scope of the FDA probe raises the likelihood of additional delays for what has been one of the most advanced Covid-19 vaccine candidates in development. The requested data was expected to arrive this week, after which the FDA would need time to analyze it, two of the sources said.

Effective vaccines are seen as essential to help end a pandemic that has killed more than one million people worldwide.

China to provide Covid-19 vaccines to the world at reasonable price: spokesperson

The administration of President Donald Trump has pledged $1.2 billion to support development of the AstraZeneca vaccine and secure 300 million doses for the United States. Other leading companies in the US vaccine race include Pfizer Inc, Moderna Inc and Johnson & Johnson.

Regulators in the UK, Brazil, India and South Africa have allowed AstraZeneca to resume its clinical trials there.

The FDA, however, wants to determine whether similar side effects emerged in trials of other vaccines designed by AstraZeneca's coronavirus vaccine partner, researchers at Oxford University, the sources said. That does not mean the agency believes there were safety issues associated with any of these vaccines, they added.

"It just shows that the FDA is being thorough," said one of the sources.

Further complicating the situation is that the data requested by FDA is in a different format than what the US regulator requires, two of the sources said.

The FDA declined to comment on discussions involving an experimental product. Oxford did not respond to requests for comment. AstraZeneca, in a statement, said: "We are continuing to work with the FDA to facilitate review of the information needed to make a decision regarding resumption of the US trial."

VIRAL VECTOR
All of the vaccines it wants to review use a modified adenovirus as vectors to safely deliver genetic material from the target illnesses - flu, Middle East Respiratory Syndrome, and other diseases - into the body to stimulate an immune system response to fight future infection.

While other vaccine developers have used human adenoviruses for such vaccines, the Oxford researchers chose an adenovirus found in chimpanzees. They felt this would reduce the likelihood that an individual's immune system would attack the vector virus due to prior exposure rather than the intended target.

Reuters reviewed six research papers that detailed safety data of vaccines using the engineered chimpanzee adenovirus called ChAdOx1 for diseases including tuberculosis, prostate cancer and influenza.

In one of those trials, one serious adverse event cited by researchers was deemed unrelated to the vaccine.

The type of review being conducted by the FDA is generally intended to scrutinize raw data for other side effects, the sources said.

The US government's effort to speed development of a Covid-19 vaccine - and promises by Trump that one could be available prior to the Nov. 3 presidential election - has led to concerns of political interference in the regulatory process at the expense of safety. The FDA has denied this.

AstraZeneca's vaccine development could also be slowed by a change to its clinical trial protocols to show that it has met pre-determined safety and efficacy standards.

Independent safety monitors will conduct their first review of the vaccine's safety and effectiveness after 75 trial subjects become infected with Covid-19, up from the original initial review plan after about 40 infections, according to a Reuters review of protocol documents issued in July and amended in mid-September.

The safety monitors could decide to stop the trial if the vaccine proves either highly effective, and therefore should be considered for public use before the trial concludes, or if serious safety problems appear.

"Safety is likely to have been a major reason" for the change, said Thomas Lumley, chair of biostatistics at the University of Auckland who was not involved with the study.

AstraZeneca would not say why it had made the change to its protocol.

Top News

AstraZeneca / US / FDA / Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Project delays: The Sinohydro style 
    Project delays: The Sinohydro style 
  • Photo: TBS
    37,000 BO account holders sell all shares in 11 days
  • Photo: Reuters
    Monkeypox: Govt puts ports on alert 

MOST VIEWED

  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap
  • Photo: BSS/AFP
    Covax calls for urgent action to close vaccine equity gap
  • Photo: Collected
    Thousands of Covid-negative Beijing residents sent to quarantine
  • A man checks phone at Lujiazui financial district in Pudong, Shanghai, China March 14, 2019. Photo :Reuters
    Shanghai inches towards Covid lockdown exit, Beijing plays defence
  • North Korean leader Kim Jong Un delivers opening remarks during the 2nd Conference of Secretaries of Primary Committees of the Workers' Party of Korea (WPK), in this photo released on February 27, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS/File Photo
    N Korea reports over 200,000 fever cases for 5th day amid Covid wave

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • China relaxes some Covid test rules for US, other travellers
  • US reopens embassy in Kyiv after closure forced by war
  • Monkeypox cases are on rise in Europe and US, here is why
  • US to suggest tariffs on Russian oil as alternative to embargoes

Features

The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters

Eco-fascism: The greenwashing of the far right

14h | Panorama
Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque

Green-backed Heron: Nothing but a prayer to catch a fish  

16h | Panorama
Illustration: TBS

‘High logistics cost weakens Bangladesh’s competitiveness’

18h | Panorama
Every morning is a new beginning for all

Seashore

19h | In Focus

More Videos from TBS

Wheat prices double in India

Wheat prices double in India

8h | Videos
Is Washington-Moscow agreement possible?

Is Washington-Moscow agreement possible?

8h | Videos
Pigeon exhibition for the first time in Gazipur

Pigeon exhibition for the first time in Gazipur

13h | Videos
Photo: TBS

US Congress to hold first public UFO panel

15h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab